HeartSciences Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
HeartSciences shows severe liquidity deterioration with cash collapsing from $1.66M to just $29,906 quarter-over-quarter, pushing the company into a stockholders' deficit of $(2.03M) from positive equity of $226K. Net loss grew 54% YoY to $3.17M driven by a more than doubling of SG&A expenses, while revenue remains negligible ($2,100 for the quarter). Current liabilities ($5.6M) now dwarf current assets ($812K), and persistent material weaknesses in internal controls raise substantial doubt about near-term operational viability.
Red Flags Detected (10)
Cash reserves fell 98% from $1,656,814 to $29,906 in one quarter
Stockholders' equity flipped from positive $226,060 to negative $(2,033,145)
Working capital deficit of approximately $4.8M (current liabilities $5.63M vs current assets $812K)
7 more red flags detected
Key Takeaways
Company is in a precarious liquidity position with under $30K cash against $5.6M in current liabilities
Business remains pre-revenue in substance despite multi-year product development (MyoVista Insights, MyoVista wavECG)
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.